Conditions: Breast Cancer
Keywords: HER-2/erbB-2 positive breast cancer breast cancer adjuvant therapy neratinib HKI-272 Nerlynx PB-272
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2840
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.

Detailed description:

Arms:
arm 1: 240 mg orally daily for one year arm 2: orally daily for one year

Interventions: intervention 1: neratinib intervention 2: placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: